MARKET

INTS

INTS

INTENSITY THERAPEUTICS INC
NASDAQ
5.46
-0.04
-0.73%
After Hours: 5.72 +0.26 +4.76% 16:22 04/13 EDT
OPEN
5.21
PREV CLOSE
5.50
HIGH
5.62
LOW
5.14
VOLUME
21.21K
TURNOVER
--
52 WEEK HIGH
50.00
52 WEEK LOW
4.633
MARKET CAP
13.87M
P/E (TTM)
-0.6381
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at INTS last week (0406-0410)?
Weekly Report · 19h ago
Weekly Report: what happened at INTS last week (0330-0403)?
Weekly Report · 04/06 09:02
INTENSITY THERAPEUTICS INC <INTS.O>: BENCHMARK ADJUSTS TARGET PRICE TO $12 FROM $1.50 TO REFLECT REVERSE STOCK SPLIT
Reuters · 03/31 11:15
U.S. RESEARCH ROUNDUP-Dutch Bros, Phreesia, Starbucks
Reuters · 03/31 07:39
Intensity Therapeutics upgraded to Buy from Hold at Freedom Broker
TipRanks · 03/30 20:00
Analysts Offer Insights on Healthcare Companies: Intensity Therapeutics, Inc. (INTS), IQVIA Holdings (IQV) and Xenon (XENE)
TipRanks · 03/30 11:30
Weekly Report: what happened at INTS last week (0323-0327)?
Weekly Report · 03/30 09:02
U.S. Tariff and Trade Policy Risks Threaten Intensity Therapeutics’ Supply Chain, Costs, and Stock Valuation
TipRanks · 03/29 06:01
More
About INTS
Intensity Therapeutics, Inc. is a late-stage clinical biotechnology company. It is engaged in developing treatments that address both the regional and systemic nature of a patient’s cancer. Its platform creates patented anti-cancer product candidates comprising active anti-cancer agents and amphiphilic molecules. Its lead product candidate, INT230-6, comprises three components: cisplatin, a proven anti-cancer cytotoxic agent, vinblastine sulfate, also a proven anti-cancer cytotoxic agent, and an amphiphilic molecule (SHAO) which enables the two cytotoxic agents to disperse through a tumor and diffuse into cancer cells following a direct intratumoral injection. Its pipeline consists of INVINCIBLE-3 Study, a Phase 3 open-label, randomized study testing the superiority INT230-6 used as monotherapy compared to the standard of care drugs in 2nd and 3rd line treatment for certain soft tissue sarcoma subtypes, a Phase 2 clinical study in metastatic triple negative breast cancer.

Webull offers Intensity Therapeutics Inc stock information, including NASDAQ: INTS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, INTS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading INTS stock methods without spending real money on the virtual paper trading platform.